// App-Quantinova.ai

: A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1)

Researchers

Presenter

  • Michael Loebinger

Principal Investigators

  • Eva Polverino

  • Francesco Blasi

  • Stuart Elborn

  • James D Chalmers

  • Harm A.W.M. Tiddens

  • Herman Goossens

  • Michael Tunney

  • Gerhild Angyalosi

  • Adam T Hill

  • Charles Haworth

Medical Centers

  • Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • University of Milan, Milan, Italy

  • University of Dundee, Dundee, United Kingdom

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • University Institution Antwerp, Antwerp, Belgium

  • Queen's University Belfast, Belfast, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Papworth Hospital, Cambridge, United Kingdom

Locations

  • United Kingdom

  • Spain

  • Italy

  • Netherlands

  • Belgium

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyzine

  • Tobramycin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved